Determine the necessary mass, volume, or concentration for preparing a solution.
for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 2 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Neomycin is an aminoglycoside antibiotic. Neomycin can be used for the research of external or internal bacterial infections, is primarily administered in veterinary medicine as a sulfate salt.
| Canonical Smiles | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N |
|---|---|
| IUPAC Name | (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol |
| InChIKey | PGBHMTALBVVCIT-VCIWKGPPSA-N |
| INCHI | 1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1 |
| Isomeric SMILES | C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N |
| Alternate CAS | 1404-04-2,119-04-0,11004-65-2,1405-10-3 (sulfate (salt)) |
| PubChem CID | 8378 |
| MeSH Entry Terms | Antibiotic 10676;Framycetin;Framycetin Sulfate;Neomycin B;Neomycin B Sulfate;Soframycin;Sulfate, Framycetin;Sulfate, Neomycin B |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Subclass | Carbohydrates and carbohydrate conjugates |
| Intermediate Tree Nodes | Aminosaccharides - Aminoglycosides - Aminocyclitol glycosides - 2-deoxystreptamine aminoglycosides |
| Direct Parent | 4,5-disubstituted 2-deoxystreptamines |
| Alternative Parents | O-glycosyl compounds Disaccharides Aminocyclitols and derivatives Cyclohexylamines Cyclohexanols Oxanes Tetrahydrofurans 1,2-aminoalcohols Oxacyclic compounds Acetals Primary alcohols Organopnictogen compounds Monoalkylamines Hydrocarbon derivatives |
| Molecular Framework | Aliphatic heteromonocyclic compounds |
| Substituents | 4,5-disubstituted 2-deoxystreptamine - Disaccharide - Glycosyl compound - O-glycosyl compound - Aminocyclitol or derivatives - Cyclohexanol - Cyclohexylamine - Cyclitol or derivatives - Oxane - Tetrahydrofuran - Cyclic alcohol - Secondary alcohol - 1,2-aminoalcohol - Acetal - Organoheterocyclic compound - Oxacycle - Primary alcohol - Hydrocarbon derivative - Organopnictogen compound - Primary aliphatic amine - Organonitrogen compound - Organic nitrogen compound - Amine - Alcohol - Primary amine - Aliphatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as 4,5-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C5-positions. |
| External Descriptors | 2-Deoxystreptamines |
| 1. Liu Shuan, Dong Zhenlin, Tang Wenjie, Zhou Jian, Guo Liu, Gong Chengyan, Liu Guang, Wan Dan, Yin Yulong. (2023) Dietary iron regulates intestinal goblet cell function and alleviates Salmonella typhimurium invasion in mice. Science China-Life Sciences, [PMID:37340176] [10.1007/s11427-022-2298-1] |
| 2. Cairong Zhang, Jie Ma, Wenling Wang, Min Guo, Cuiliu Han, Madinamu Sadike, Kaichun Zhu. (2026) LINC00473 modulates protein expression to promote ovarian cancer progression and overcome cisplatin resistance. Oncology Letters, 31 (3): (1-11). [PMID:41560976] [10.3892/ol.2026.15456] |